Thank you for downloading this publication. Please let us know why you chose this publication:
Why are you interested in this publication?
What organisation do you represent?
You will only need to complete this form once per browser/device
How do you prefer to read or receive publications?

We may contact you for feedback on the publication you have downloaded. If you do not want to be contacted, please leave the email field blank. Your information will never be shared with any third party.

Malaria Consortium US Donate
  • About us
    • Who we are
    • Our Strategy
    • Governance
    • Aid transparency
  • Projects
  • Where We Work
  • What we do
    • Diseases
    • Our responses
    • Burden reduction to elimination
    • Data-informed decision-making & digital approaches
    • Health sector resilience
    • Research & policy change
    • Networks & partnerships
  • News & Resources
    • News
    • Blog
    • Videos
    • Webinars
    • Photo stories
  • Publications
    • Interactive publications
  • Support us
  • Contact Us
    • Newsletter
  • Work with us
    • Tenders
    • Scholarships
  • Home
  • »
  • Publications
  • »
  • Consequences of restricting antimalarial drugs to rapid diagnostic test-positive febrile children in south-west Nigeria

Share this page

Resources

Latest

Publications

Publication Date:
18/11/2019

Type:
Journal article
Publication

Consequences of restricting antimalarial drugs to rapid diagnostic test-positive febrile children in south-west Nigeria
Author(s): Catherine Olufunke Falade, Adebola Emanuel Orimadegun, Obaro Stanley Michael, Hannah Odunola Dada-Adegbola, Oluwatoyin Oluwafunmilayo Ogunkunle, Joseph Ayotunde Badejo, Roland Ibenipere Funwei, IkeOluwapo Oyeneye Ajayi, Ayodele Samuel Jegede, Olusola Daniel Ojurongbe, James Ssekitooleko, Ebenezer Baba, Prudence Hamade, Jayne Webster, Daniel Chandramohan

Publication Date:
18/11/2019
Type:
Journal article

Objectives

To investigate the consequence of restricting antimalarial treatment to febrile children that test positive to a malaria rapid diagnostic test (mRDT) only in an area of intense malaria transmission.

Methods

Febrile children aged 3–59 months were screened with an mRDT at health facilities in south-west Nigeria. mRDT-positive children received artesunate–amodiaquine (ASAQ), while mRDT-negative children were treated based on the clinical diagnosis of non-malaria febrile illness. The primary endpoint was the risk of developing microscopy-positive malaria within 28 days post-treatment.

Results

309 (60.5%) of 511 children were mRDT-positive while 202 (39.5%) were mRDT-negative at enrolment. 18.5% (50/275) of mRDT-positive children and 7.6% (14/184) of mRDT-negative children developed microscopy-positive malaria by day 28 post-treatment (q = 0.001). The risk of developing clinical malaria by day 28 post-treatment was higher among the mRDT-positive group than the mRDT-negative group (adjusted OR 2.74; 95% CI, 1.4, 5.4). A higher proportion of children who were mRDT-positive at enrolment were anaemic on day 28 compared with the MRDT-negative group (12.6% vs. 3.1%; q = 0.001). Children in the mRDT-negative group made more unscheduled visits because of febrile illness than those in mRDT-positive group (23.2% vs. 12.0%; q = 0.001).

Conclusion

Restricting ACT treatment to mRDT-positive febrile children only did not result in significant adverse outcomes. However, the risk of re-infection within 28 days was significantly higher among mRDT-positive children despite ASAQ treatment. A longer-acting ACT may be needed as the first-line drug of choice for treating uncomplicated malaria in high-transmission settings to
prevent frequent re-infections.

Click here to download

Country: Nigeria

Keywords: Research | Malaria | Diagnosis | SDG3

 

 

« Back to Publications

Sign up for our newsletter here:

Follow us on our social channels
  • Jobs
  • Contact us
  • Annual reviews
  • Support us
  • About us
  • Sitemap
  • Policies
  • Modern Slavery Statement
Fundraising Regulator logo
© 2023 Malaria Consortium | Charity No. 1099776 | Company No. 4785712